PPARG and lung carcinoma: Last but not least, the impact of the new 4-TZD-based molecules on PPARγ and their possible agonist properties have been shown in different human cell lines, such as normal fibroblast (BJ), squamous cell carcinoma (SCC-15), lung carcinoma (A549), colon adenocarcinoma (CACO-2), and neuroblastoma (SH-SY5Y) cells [13,37,38,39].